A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Clinical trial NCT00739453 · COMPLETED

Trial details

NCT number: NCT00739453
Sponsor: Astellas Pharma Inc
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors

Start date: 2008-10-23
Primary completion: 2012-03-03
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.